Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Phase 1 Recruiting
495 enrolled
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Phase 1 Completed
269 enrolled
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Phase 1 Completed
9 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Phase 1 Completed
7 enrolled
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Phase 1 Withdrawn
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Phase 1 Completed
236 enrolled 21 charts
FABLOx
Phase 1 Completed
12 enrolled
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Phase 1 Completed
66 enrolled
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Phase 1 Completed
17 enrolled
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Phase 1 Completed
180 enrolled
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Phase 1 Completed
32 enrolled 13 charts
TART
Phase 1 Completed
12 enrolled 6 charts
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
Phase 1 Completed
48 enrolled